Aptinyx Inc (APTX)

OTC Markets
Currency in USD
Disclaimer
0.062
0.000(0.00%)
Closed
Day's Range
0.0620.066
52 wk Range
0.0310.720
Prev. Close
0.062
Open
0.066
Day's Range
0.062-0.066
52 wk Range
0.031-0.72
Volume
2,849
Average Vol. (3m)
53,274
1-Year Change
-74.13%
Shares Outstanding
67,715,718
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More
How do you feel today about APTX?
Vote to see community's results!
or

Aptinyx Inc Company Profile

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

Employees
12